Fig. 4
Timeline of FDA approvals for ICIs targeting T-cells, B-cells, TAMs, CAFs, and tumor vasculature. Timeline of FDA approvals for ICIs targeting T-cells (blue rectangles), B-cells (red rectangles), TAMs (orange rectangle), CAFs (yellow rectangles), and tumor vasculature (green rectangles) is shown. Black arrows below the ICIs: years in which the first FDA approval occurred. Grey squares at the top-left of each inhibitor: cancer type/s related to the first FDA approval of the corresponding inhibitor. ASTs: Advanced solid tumors; BCC: Basal cell carcinoma; CLL: Chronic lymphocytic leukemia; CRC: Colorectal cancer; GC: Gastric cancer; GISTs: Gastrointestinal stromal tumors; HCC: Hepatocellular carcinoma; HL: Hodgkin lymphoma; MCL: Mantle cell lymphoma; MEL: Melanoma; MZL: Marginal zone lymphoma; NSCLC: Non-small cell lung cancer; PC: Pancreatic cancer; RCC: Renal cell carcinoma; SLL: Acute lymphocytic leukemia; STS: Soft tissue sarcoma; TC: Thyroid cancer; TGCTs: Tenosynovial giant cell tumors; UC: Urothelial cancer; WM: Waldenström macroglobulinemia. Asterisk (*) beside grey-squared ASTs: year in which the first (of a series of) AST FDA approval occurred for a particular ICI. Circled capital letters at the top-right of each inhibitor: biopharmaceutical companies related to the first FDA approval of inhibitors. Ⓐ: AstraZeneca; Ⓑ: Bayer AG; Ⓓ: Daiichi Sankyo Company; Ⓔ: Eli Lilly and Company; Ⓖ: GlaxoSmithKline (GSK); Ⓙ: Janssen Pharmaceuticals, Inc; Ⓜ: Merck Inc; Ⓝ: Novartis; Ⓟ: Pfizer Inc; Ⓡ: Bristol-Myers Squibb Company; Ⓢ: Sanofi SA; Ⓣ: Genentech Inc; Ⓥ: AbbVie Inc